IBDEI3AT ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4,59,0)
;;=PROCEDURE CODES^3^12
;;^UTILITY(U,$J,358.4,60,0)
;;=FAMILY TRAINING-GROUP^2^12
;;^UTILITY(U,$J,358.4,61,0)
;;=RECREATION THERAPY DX^1^13
;;^UTILITY(U,$J,358.4,62,0)
;;=1-1 THERAPEUTIC PROCEDURES^1^14
;;^UTILITY(U,$J,358.4,63,0)
;;=EDUCATION/TRAINING^3^14
;;^UTILITY(U,$J,358.4,64,0)
;;=TEAM CONFERENCE^6^14
;;^UTILITY(U,$J,358.4,65,0)
;;=ASSESSMENT^2^14
;;^UTILITY(U,$J,358.4,66,0)
;;=FAMILY TRAINING^4^14
;;^UTILITY(U,$J,358.4,67,0)
;;=SPECIALTY PROCEDURES-INDIVIDUAL^5^14
;;^UTILITY(U,$J,358.4,68,0)
;;=RECREATION THERAPY DX^1^15
;;^UTILITY(U,$J,358.4,69,0)
;;=RESPIRATORY^10^16
;;^UTILITY(U,$J,358.4,70,0)
;;=SLEEP TESTING AND EVAL^11^16
;;^UTILITY(U,$J,358.4,71,0)
;;=PULMONARY FUNCTION TESTS^9^16
;;^UTILITY(U,$J,358.4,72,0)
;;=ABG/OX/TRANSCUTANEUOUS^1^16
;;^UTILITY(U,$J,358.4,73,0)
;;=HOME OXYGEN CLINIC^6^16
;;^UTILITY(U,$J,358.4,74,0)
;;=CPAP^2^16
;;^UTILITY(U,$J,358.4,75,0)
;;=EDUCATION/TRAINING^3^16
;;^UTILITY(U,$J,358.4,76,0)
;;=PROLONGED CLINICAL STAFF SERVICES^8^16
;;^UTILITY(U,$J,358.4,77,0)
;;=HOME SLEEP STUDIES^7^16
;;^UTILITY(U,$J,358.4,78,0)
;;=TELEHEALTH PATIENT SITE^12^16
;;^UTILITY(U,$J,358.4,79,0)
;;=NEW PATIENT^2^17
;;^UTILITY(U,$J,358.4,80,0)
;;=ESTABLISHED PATIENT^1^17
;;^UTILITY(U,$J,358.4,81,0)
;;=CONSULTATIONS^3^17
;;^UTILITY(U,$J,358.4,82,0)
;;=PULMONARY DIAGNOSES^2^18
;;^UTILITY(U,$J,358.4,83,0)
;;=SLEEP DX PRELIMINARY^3^18
;;^UTILITY(U,$J,358.4,84,0)
;;=SLEEP DX CONFIRMED^4^18
;;^UTILITY(U,$J,358.4,85,0)
;;=OTHER SLEEP RELATED DX^6^18
;;^UTILITY(U,$J,358.4,86,0)
;;=SUICIDE IDEATIONS/ATTEMPTS^5^18
;;^UTILITY(U,$J,358.4,87,0)
;;=OBESITY & BMI DX^1^18
;;^UTILITY(U,$J,358.4,88,0)
;;=SPECIAL SERVICES^6^19
;;^UTILITY(U,$J,358.4,89,0)
;;=TREATMENT^7^19
;;^UTILITY(U,$J,358.4,90,0)
;;=MISCELLANEOUS^4^19
;;^UTILITY(U,$J,358.4,91,0)
;;=IMMUNIZATIONS^3^19
;;^UTILITY(U,$J,358.4,92,0)
;;=CHEMO ADMINISTRATION^1^19
;;^UTILITY(U,$J,358.4,93,0)
;;=CHEMO DRUGS^2^19
;;^UTILITY(U,$J,358.4,94,0)
;;=OTHER DRUGS^5^19
;;^UTILITY(U,$J,358.4,95,0)
;;=NEW PATIENT^2^20
;;^UTILITY(U,$J,358.4,96,0)
;;=ESTABLISHED PATIENT^1^20
;;^UTILITY(U,$J,358.4,97,0)
;;=CONSULTATIONS^3^20
;;^UTILITY(U,$J,358.4,98,0)
;;=POST OP^4^20
;;^UTILITY(U,$J,358.4,99,0)
;;=ANEMIA^2^21
;;^UTILITY(U,$J,358.4,100,0)
;;=BREAST & GYN NEOPLASMS^2^21
;;^UTILITY(U,$J,358.4,101,0)
;;=COAGULATION DISORDERS^3^21
;;^UTILITY(U,$J,358.4,102,0)
;;=COUNSELING & SCREENING^4^21
;;^UTILITY(U,$J,358.4,103,0)
;;=GENITOURINARY NEOPLASMS^5^21
;;^UTILITY(U,$J,358.4,104,0)
;;=GI CANCER^6^21
;;^UTILITY(U,$J,358.4,105,0)
;;=HEAD/NECK/LUNG CANCER^7^21
;;^UTILITY(U,$J,358.4,106,0)
;;=HEMOGLOBINOPATHIES^9^21
;;^UTILITY(U,$J,358.4,107,0)
;;=LYMPHOID NEOPLASMS^10^21
;;^UTILITY(U,$J,358.4,108,0)
;;=METASTATIC SITES^11^21
;;^UTILITY(U,$J,358.4,109,0)
;;=MISC. NEOPLASMS^12^21
;;^UTILITY(U,$J,358.4,110,0)
;;=MYELOID NEOPLASMS/DISORDERS^13^21
;;^UTILITY(U,$J,358.4,111,0)
;;=PERSONAL HX OF CANCER^15^21
;;^UTILITY(U,$J,358.4,112,0)
;;=OTHER^14^21
;;^UTILITY(U,$J,358.4,113,0)
;;=HEMATOLOGICAL^8^21
;;^UTILITY(U,$J,358.4,114,0)
;;=SYMPTOMS^17^21
;;^UTILITY(U,$J,358.4,115,0)
;;=TREATMENT^18^21
;;^UTILITY(U,$J,358.4,116,0)
;;=SUICIDE IDEATIONS/ATTEMPTS^16^21
;;^UTILITY(U,$J,358.4,117,0)
;;=ABNORMAL LAB TEST RESULTS^1^21
;;^UTILITY(U,$J,358.4,118,0)
;;=SPECIAL SERVICES^10^22
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3AT 3782 printed Sep 23, 2025@20:21:12 Page 2
IBDEI3AT ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4,59,0)
+2 ;;=PROCEDURE CODES^3^12
+3 ;;^UTILITY(U,$J,358.4,60,0)
+4 ;;=FAMILY TRAINING-GROUP^2^12
+5 ;;^UTILITY(U,$J,358.4,61,0)
+6 ;;=RECREATION THERAPY DX^1^13
+7 ;;^UTILITY(U,$J,358.4,62,0)
+8 ;;=1-1 THERAPEUTIC PROCEDURES^1^14
+9 ;;^UTILITY(U,$J,358.4,63,0)
+10 ;;=EDUCATION/TRAINING^3^14
+11 ;;^UTILITY(U,$J,358.4,64,0)
+12 ;;=TEAM CONFERENCE^6^14
+13 ;;^UTILITY(U,$J,358.4,65,0)
+14 ;;=ASSESSMENT^2^14
+15 ;;^UTILITY(U,$J,358.4,66,0)
+16 ;;=FAMILY TRAINING^4^14
+17 ;;^UTILITY(U,$J,358.4,67,0)
+18 ;;=SPECIALTY PROCEDURES-INDIVIDUAL^5^14
+19 ;;^UTILITY(U,$J,358.4,68,0)
+20 ;;=RECREATION THERAPY DX^1^15
+21 ;;^UTILITY(U,$J,358.4,69,0)
+22 ;;=RESPIRATORY^10^16
+23 ;;^UTILITY(U,$J,358.4,70,0)
+24 ;;=SLEEP TESTING AND EVAL^11^16
+25 ;;^UTILITY(U,$J,358.4,71,0)
+26 ;;=PULMONARY FUNCTION TESTS^9^16
+27 ;;^UTILITY(U,$J,358.4,72,0)
+28 ;;=ABG/OX/TRANSCUTANEUOUS^1^16
+29 ;;^UTILITY(U,$J,358.4,73,0)
+30 ;;=HOME OXYGEN CLINIC^6^16
+31 ;;^UTILITY(U,$J,358.4,74,0)
+32 ;;=CPAP^2^16
+33 ;;^UTILITY(U,$J,358.4,75,0)
+34 ;;=EDUCATION/TRAINING^3^16
+35 ;;^UTILITY(U,$J,358.4,76,0)
+36 ;;=PROLONGED CLINICAL STAFF SERVICES^8^16
+37 ;;^UTILITY(U,$J,358.4,77,0)
+38 ;;=HOME SLEEP STUDIES^7^16
+39 ;;^UTILITY(U,$J,358.4,78,0)
+40 ;;=TELEHEALTH PATIENT SITE^12^16
+41 ;;^UTILITY(U,$J,358.4,79,0)
+42 ;;=NEW PATIENT^2^17
+43 ;;^UTILITY(U,$J,358.4,80,0)
+44 ;;=ESTABLISHED PATIENT^1^17
+45 ;;^UTILITY(U,$J,358.4,81,0)
+46 ;;=CONSULTATIONS^3^17
+47 ;;^UTILITY(U,$J,358.4,82,0)
+48 ;;=PULMONARY DIAGNOSES^2^18
+49 ;;^UTILITY(U,$J,358.4,83,0)
+50 ;;=SLEEP DX PRELIMINARY^3^18
+51 ;;^UTILITY(U,$J,358.4,84,0)
+52 ;;=SLEEP DX CONFIRMED^4^18
+53 ;;^UTILITY(U,$J,358.4,85,0)
+54 ;;=OTHER SLEEP RELATED DX^6^18
+55 ;;^UTILITY(U,$J,358.4,86,0)
+56 ;;=SUICIDE IDEATIONS/ATTEMPTS^5^18
+57 ;;^UTILITY(U,$J,358.4,87,0)
+58 ;;=OBESITY & BMI DX^1^18
+59 ;;^UTILITY(U,$J,358.4,88,0)
+60 ;;=SPECIAL SERVICES^6^19
+61 ;;^UTILITY(U,$J,358.4,89,0)
+62 ;;=TREATMENT^7^19
+63 ;;^UTILITY(U,$J,358.4,90,0)
+64 ;;=MISCELLANEOUS^4^19
+65 ;;^UTILITY(U,$J,358.4,91,0)
+66 ;;=IMMUNIZATIONS^3^19
+67 ;;^UTILITY(U,$J,358.4,92,0)
+68 ;;=CHEMO ADMINISTRATION^1^19
+69 ;;^UTILITY(U,$J,358.4,93,0)
+70 ;;=CHEMO DRUGS^2^19
+71 ;;^UTILITY(U,$J,358.4,94,0)
+72 ;;=OTHER DRUGS^5^19
+73 ;;^UTILITY(U,$J,358.4,95,0)
+74 ;;=NEW PATIENT^2^20
+75 ;;^UTILITY(U,$J,358.4,96,0)
+76 ;;=ESTABLISHED PATIENT^1^20
+77 ;;^UTILITY(U,$J,358.4,97,0)
+78 ;;=CONSULTATIONS^3^20
+79 ;;^UTILITY(U,$J,358.4,98,0)
+80 ;;=POST OP^4^20
+81 ;;^UTILITY(U,$J,358.4,99,0)
+82 ;;=ANEMIA^2^21
+83 ;;^UTILITY(U,$J,358.4,100,0)
+84 ;;=BREAST & GYN NEOPLASMS^2^21
+85 ;;^UTILITY(U,$J,358.4,101,0)
+86 ;;=COAGULATION DISORDERS^3^21
+87 ;;^UTILITY(U,$J,358.4,102,0)
+88 ;;=COUNSELING & SCREENING^4^21
+89 ;;^UTILITY(U,$J,358.4,103,0)
+90 ;;=GENITOURINARY NEOPLASMS^5^21
+91 ;;^UTILITY(U,$J,358.4,104,0)
+92 ;;=GI CANCER^6^21
+93 ;;^UTILITY(U,$J,358.4,105,0)
+94 ;;=HEAD/NECK/LUNG CANCER^7^21
+95 ;;^UTILITY(U,$J,358.4,106,0)
+96 ;;=HEMOGLOBINOPATHIES^9^21
+97 ;;^UTILITY(U,$J,358.4,107,0)
+98 ;;=LYMPHOID NEOPLASMS^10^21
+99 ;;^UTILITY(U,$J,358.4,108,0)
+100 ;;=METASTATIC SITES^11^21
+101 ;;^UTILITY(U,$J,358.4,109,0)
+102 ;;=MISC. NEOPLASMS^12^21
+103 ;;^UTILITY(U,$J,358.4,110,0)
+104 ;;=MYELOID NEOPLASMS/DISORDERS^13^21
+105 ;;^UTILITY(U,$J,358.4,111,0)
+106 ;;=PERSONAL HX OF CANCER^15^21
+107 ;;^UTILITY(U,$J,358.4,112,0)
+108 ;;=OTHER^14^21
+109 ;;^UTILITY(U,$J,358.4,113,0)
+110 ;;=HEMATOLOGICAL^8^21
+111 ;;^UTILITY(U,$J,358.4,114,0)
+112 ;;=SYMPTOMS^17^21
+113 ;;^UTILITY(U,$J,358.4,115,0)
+114 ;;=TREATMENT^18^21
+115 ;;^UTILITY(U,$J,358.4,116,0)
+116 ;;=SUICIDE IDEATIONS/ATTEMPTS^16^21
+117 ;;^UTILITY(U,$J,358.4,117,0)
+118 ;;=ABNORMAL LAB TEST RESULTS^1^21
+119 ;;^UTILITY(U,$J,358.4,118,0)
+120 ;;=SPECIAL SERVICES^10^22
